Akt1

AKT1 (protein kinase Bα, PKBα) is a serine/threonine kinase that functions as a central effector of the PI3K/AKT/mTOR signaling pathway, regulating cellular growth, survival, metabolism, proliferation, and differentiation across multiple tissues and cell types^[1][2][3]. Activation of AKT1 occurs downstream of PI3K through phosphoinositide-dependent kinase-1 (PDK1)-mediated phosphorylation, enabling downstream regulation of targets involved in protein synthesis, apoptosis control, and metabolic adaptation^[4][5]. Mechanistically, AKT1 contributes to angiogenesis, physiological tissue growth, immune-cell function, and stress-response signaling, making it a critical node in both normal physiology and disease-associated signaling networks^[2][4][5]. In disease models, dysregulated AKT signaling is strongly associated with cancer, metabolic disorders, cardiovascular pathology, and inflammatory conditions, and constitutive activation of AKT-dependent pathways promotes oncogenic progression and therapeutic resistance^[2][6][7]. Compared with related isoforms, AKT1 exhibits distinct biological functions despite substantial structural homology with AKT2 and AKT3; genetic studies demonstrate that AKT1 deficiency primarily causes growth retardation, whereas AKT2 deficiency induces insulin resistance and diabetes, and AKT3 loss predominantly affects brain development^[4][5]. Isoform-specific investigations further show that AKT1 and AKT2 can exert non-redundant or even opposing effects on migration, invasion, inflammation, and fibrogenesis depending on cellular context^[2][6][8]. For experimental applications, increasing efforts focus on developing AKT1-selective inhibitors and isoform-selective cellular models, which provide valuable tools for dissecting AKT isoform-specific signaling and for evaluating targeted therapeutic strategies with improved selectivity profiles^[6][7][9].